Yahoo Web Search

Search results

1. • Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of...

     KSAN - KLST San Angelo· 3 hours ago

     Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...

2. • Ocular Therapeutix Inc Reports First Quarter 2024 Earnings

     Guru Focus· 1 day ago

     Revenue: Reported $14.8 million, a 10.4% increase year-over-year, falling short of the estimated $15.41 million.Net Loss: Increased to $(64.8) million from $(3

3. • 

     How AI Has Already Begun to Change These Workers’ Jobs

     The Wall Street Journal· 13 hours ago

     Artificial intelligence hasn’t been the job killer that some predicted, at least not so far. Census...

4. • EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint

     Market Watch· 3 days ago

     EyePoint Pharmaceuticals said that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.

5. • 

     Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

     Investor's Business Daily· 6 days ago

     Regeneron stock jumped Thursday, bolstered by strong sales of a high-dose version of its blockbuster...

6. • 

     5 health behaviors that can make you blind

     Rolling Out· 1 day ago

     Most of us are aware that certain diseases or injuries can lead to vision loss but not realize that everyday behaviors can also harm our sight.

7. • 

     HanAll Biopharma initiates Phase III DED treatment trial

     Clinical Trials Arena via Yahoo Finance· 3 days ago

     HanAll Biopharma has commenced the Phase III VELOS-4 trial for tanfanercept, a new topical...

8. • ...Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for...

     FOX 4 Kansas City· 6 days ago

     HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. Tanfanercept demonstrated ...

9. • Q1 2024 Halozyme Therapeutics Inc Earnings Call

     Thomson Reuters StreetEvents via Yahoo Finance· 16 hours ago

     We're also pleased to report two pipeline advancements. Firstly, our Agennix initiated registrational studies of efgartigimod subcutaneous with Enhanze for a new indication thyroid ...

10. • 

      NovaBay reports record Avenova sales on Amazon By Investing.com

      Investing.com· 1 day ago

      NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has announced a significant uptick in sales for...